Haemonetics (HAE) Competitors

$55.74 +1.37 (+2.51%)

As of 03:10 PM Eastern

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). These companies are all part of the "medical" sector.

How does Haemonetics compare to DexCom?

DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

DexCom has a net margin of 19.31% compared to Haemonetics' net margin of 13.31%. DexCom's return on equity of 33.33% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Haemonetics	13.31%	27.32%	9.61%

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DexCom has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	5.01	$836.30M	$2.34	25.85
Haemonetics	$1.36B	1.90	$167.68M	$3.63	15.35

In the previous week, DexCom had 10 more articles in the media than Haemonetics. MarketBeat recorded 28 mentions for DexCom and 18 mentions for Haemonetics. DexCom's average media sentiment score of 0.90 beat Haemonetics' score of 0.68 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	16 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom currently has a consensus price target of $83.50, indicating a potential upside of 38.03%. Haemonetics has a consensus price target of $81.22, indicating a potential upside of 45.73%. Given Haemonetics' higher probable upside, analysts clearly believe Haemonetics is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

DexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

Haemonetics (NYSE:HAE) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

HealthEquity has a net margin of 16.39% compared to Haemonetics' net margin of 13.31%. Haemonetics' return on equity of 27.32% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	13.31%	27.32%	9.61%
HealthEquity	16.39%	13.86%	8.67%

Haemonetics presently has a consensus price target of $81.22, indicating a potential upside of 45.73%. HealthEquity has a consensus price target of $111.79, indicating a potential upside of 32.69%. Given Haemonetics' higher possible upside, equities analysts plainly believe Haemonetics is more favorable than HealthEquity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

HealthEquity has lower revenue, but higher earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36B	1.90	$167.68M	$3.63	15.35
HealthEquity	$1.31B	5.42	$215.20M	$2.46	34.25

In the previous week, Haemonetics had 10 more articles in the media than HealthEquity. MarketBeat recorded 18 mentions for Haemonetics and 8 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.36 beat Haemonetics' score of 0.68 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 1.5% of HealthEquity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Haemonetics beats HealthEquity on 9 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Lantheus has a net margin of 15.15% compared to Haemonetics' net margin of 13.31%. Lantheus' return on equity of 30.77% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	15.15%	30.77%	16.10%
Haemonetics	13.31%	27.32%	9.61%

Lantheus currently has a consensus price target of $97.29, indicating a potential upside of 4.28%. Haemonetics has a consensus price target of $81.22, indicating a potential upside of 45.73%. Given Haemonetics' higher probable upside, analysts clearly believe Haemonetics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

99.1% of Lantheus shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Lantheus has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	3.94	$233.56M	$3.37	27.68
Haemonetics	$1.36B	1.90	$167.68M	$3.63	15.35

In the previous week, Lantheus and Lantheus both had 18 articles in the media. Lantheus' average media sentiment score of 0.88 beat Haemonetics' score of 0.68 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Haemonetics on 9 of the 15 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Haemonetics (NYSE:HAE) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Haemonetics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Haemonetics presently has a consensus price target of $81.22, indicating a potential upside of 45.73%. Insulet has a consensus price target of $257.09, indicating a potential upside of 65.87%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Insulet	1 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.71

Insulet has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36B	1.90	$167.68M	$3.63	15.35
Insulet	$2.71B	3.96	$247.10M	$3.50	44.28

Haemonetics has a net margin of 13.31% compared to Insulet's net margin of 10.44%. Haemonetics' return on equity of 27.32% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	13.31%	27.32%	9.61%
Insulet	10.44%	26.87%	12.01%

99.7% of Haemonetics shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by company insiders. Comparatively, 0.4% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Insulet had 37 more articles in the media than Haemonetics. MarketBeat recorded 55 mentions for Insulet and 18 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.68 beat Insulet's score of 0.19 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	12 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insulet beats Haemonetics on 9 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Haemonetics had 9 more articles in the media than Quanterix. MarketBeat recorded 18 mentions for Haemonetics and 9 mentions for Quanterix. Haemonetics' average media sentiment score of 0.68 beat Quanterix's score of 0.37 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quanterix has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$144.74M	0.91	-$107.15M	-$2.36	N/A
Haemonetics	$1.36B	1.90	$167.68M	$3.63	15.35

Quanterix presently has a consensus target price of $4.00, indicating a potential upside of 42.60%. Haemonetics has a consensus target price of $81.22, indicating a potential upside of 45.73%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Haemonetics has a net margin of 13.31% compared to Quanterix's net margin of -71.86%. Haemonetics' return on equity of 27.32% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.55%	-17.17%
Haemonetics	13.31%	27.32%	9.61%

Summary

Haemonetics beats Quanterix on 16 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$2.59B	$7.96B	$6.18B	$22.84B
Dividend Yield	N/A	2.45%	2.78%	4.01%
P/E Ratio	15.35	123.30	28.57	28.26
Price / Sales	1.90	7.65	505.98	23.92
Price / Cash	7.31	17.04	43.30	25.49
Price / Book	3.41	3.50	9.99	4.65
Net Income	$167.68M	$223.69M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-0.61%
1 Month Performance	-6.13%	8.62%	4.62%	4.16%
1 Year Performance	-18.21%	2.13%	40.35%	28.70%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	4.2861 of 5 stars	$55.74 +2.5%	$81.22 +45.7%	-15.2%	$2.59B	$1.36B	15.35	3,023	Trending News Earnings Report Analyst Forecast
DXCM DexCom	4.8381 of 5 stars	$61.41 -0.3%	$86.50 +40.9%	-26.9%	$23.76B	$4.66B	29.24	11,000
HQY HealthEquity	4.4658 of 5 stars	$83.52 +1.3%	$111.79 +33.8%	-8.5%	$6.97B	$1.31B	33.95	2,814	Positive News
LNTH Lantheus	3.4381 of 5 stars	$84.11 -0.3%	$88.86 +5.6%	+13.0%	$5.49B	$1.54B	24.96	1,193	Trending News Earnings Report Analyst Forecast
PODD Insulet	4.9532 of 5 stars	$188.31 -0.7%	$327.24 +73.8%	-39.2%	$13.13B	$2.71B	53.80	5,400	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Is DXCM or HAE more profitable?

Do institutionals & insiders hold more shares of DXCM or HAE?

Which has more risk and volatility, DXCM or HAE?

Which has higher valuation & earnings, DXCM or HAE?

Does the media prefer DXCM or HAE?

Do analysts prefer DXCM or HAE?

Summary

How does Haemonetics compare to HealthEquity?

Is HAE or HQY more profitable?

Do analysts recommend HAE or HQY?

Which has better earnings and valuation, HAE or HQY?

Does the media favor HAE or HQY?

Which has more risk and volatility, HAE or HQY?

Do insiders and institutionals believe in HAE or HQY?

Summary

How does Haemonetics compare to Lantheus?

Is LNTH or HAE more profitable?

Do analysts prefer LNTH or HAE?

Do insiders & institutionals believe in LNTH or HAE?

Which has more risk & volatility, LNTH or HAE?

Which has better valuation and earnings, LNTH or HAE?

Does the media refer more to LNTH or HAE?

Summary

How does Haemonetics compare to Insulet?

Which has more volatility and risk, HAE or PODD?

Do analysts prefer HAE or PODD?

Which has better valuation & earnings, HAE or PODD?

Is HAE or PODD more profitable?

Do insiders and institutionals believe in HAE or PODD?

Does the media prefer HAE or PODD?

Summary

How does Haemonetics compare to Quanterix?

Does the media favor QTRX or HAE?

Which has more risk & volatility, QTRX or HAE?

Do institutionals and insiders believe in QTRX or HAE?

Which has higher earnings and valuation, QTRX or HAE?

Do analysts rate QTRX or HAE?

Is QTRX or HAE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools